Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 10, No 1 (2017) RESTRICTIVE LISTS OF DRUGS: REGULATIONS, FUNCTIONS, SOURCES OF FINANCE, AND GUIDELINES FOR CREATION Abstract  similar documents
M. V. Sura
"... and sources of finance pertaining to the restrictive lists of drugs, which play a substantial role in the drug ..."
 
Vol 10, No 3 (2017) The strategies of drug supply for patients with chronic hepatitis C Abstract  similar documents
E. V. Kornilova, A. D. Ermolaeva, M. G. Rusanova, D. A. Andreev, M. V. Davydovskaya, T. N. Ermolaeva, A. g Pokatilo, K. I. Polyakova, V. A. Dubovtseva, K. А. Kokushkin, A. V. Devyatkin
"... The report reviews the options of drug supply for patients with chronic hepatitis C in the Russian ..."
 
Vol 10, No 2 (2017) COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS Abstract  similar documents
M. B. Kubaeva, Y. Sh. Guchshina
"... of anti-HIV drugs. Material and methods. The study was based on the documented medical histories of HIV ..."
 
Vol 10, No 3 (2017) Review of the current approaches to the assessment of the drug innovative potential worldwide Abstract  similar documents
N. Z. Musina, V. K. Fedyaeva, V. V. Omel’yanovskii, G. R. Khachatryan, K. V. Gerasimova, V. A. Lemeshko, K. P. Konchits
"... A set of criteria for assessing the innovative potential of drugs (therapeutic value) have been ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... aspects) drug for the treatment of widespread progressing differentiated thyroid cancer (DTC) refractory ..."
 
Vol 10, No 2 (2017) THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS Abstract  similar documents
V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko
 
Vol 10, No 1 (2017) PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS Abstract  similar documents
A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina
"... that the introduction of brentuximab vetodin in the List of vital and essential drugs and the Program of state ..."
 
Vol 9, No 4 (2016) PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION Abstract  similar documents
D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya
"... Objective. Pharmacoeconomic analysis of the use of combinations of antihypertensive drugs were ..."
 
Vol 10, No 3 (2017) Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients Abstract  similar documents
N. K. Mazina, P. V. Mazin
"... analysis of patient management was conducted for each of the three drugs. The direct costs included ..."
 
Vol 10, No 2 (2017) COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
"... The recently introduced novel drug combinations for the treatment of COPD are based on long-acting ..."
 
Vol 10, No 2 (2017) PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY Abstract  similar documents
A. V. Rudakova, S. A. Protsenko, I. A. Koroleva
"... on pricing entered with no discounts for a period of 1-5 years. The costs of the immunotherapeutic drugs were ..."
 
Vol 10, No 3 (2017) ABC-analysis of pharmacotherapy in children hospitalized with bronchial asthma exacerbations Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... . In relation to the field of medicinal use, the analyzed drugs were distributed into three classes (A, B and C ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... ) was used as the main criterion of effectiveness. Direct medical costs of drug therapy, and the costs ..."
 
Vol 10, No 1 (2017) CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS Abstract  similar documents
P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova
"... Innovative drugs eribulin and trabectedin are effective in the treatment of soft tissue sarcomas ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... of drugs from the list of vital and essential drugs (VED), the size of the maximal wholesale mark-ups ..."
 
Vol 10, No 1 (2017) THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES Abstract  similar documents
N. Z. Musina, V. K. Fedyaeva
"... of QALY as a measure of drug effectiveness is not yet possible because of the lack of standardized ..."
 
Vol 10, No 3 (2017) Decision modelling for the evaluation of diabetes outcomes Abstract  similar documents
A. A. Mosikian, W. Zhao, T. L. Galankin, A. S. Kolbin
"... or to some aspects of the disease. Thus, the use of the novel anti-diabetic drugs (liraglutide, semaglutide ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... of registration in the case of inclusion in the Essential Drugs List (0,5% R-R amp. 10 ml №10 – 947,74 RUB; 0 ..."
 
Vol 10, No 1 (2017) PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM Abstract  similar documents
N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova
"... Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y ..."
 
Vol 10, No 2 (2017) CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... between the original and generic drugs, and to evaluate the treatment of acute diseases. With respect ..."
 
1 - 20 of 20 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)